This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Law Offices Of Nicholas Koluncich III, LLC Announces Investigation Of Impax Laboratories (NASDAQ: IPXL) – Seeking Current Shareholders

Stocks in this article: IPXL

The Law Offices of Nicholas Koluncich III, LLC is investigating possible breaches of fiduciary duty by certain officers and directors of Impax Laboratories (NASDAQ IPXL) (“Impax” or “Company”). Current Impax stockholders are therefore encouraged to contact us for a free evaluation of their right to some form of financial recovery. A lawsuit is pending in United States Federal Court alleging that the Company has “Pervasive Manufacturing and QC [Quality Control] Deficiencies” and that Impax CEO Larry Hsu and CFO Arthur Koch made false statements of material fact concerning, in summary terms:

-The Company’s ability to address and correct the QC deficiencies noted by the FDA; and

-The Company’s ability to timely develop its pipeline of both generic and brand name drugs as a result of those alleged deficiencies.

That lawsuit has already survived initial judicial scrutiny at the motion to dismiss phase. Significantly, on April 24, 2014, six days after a ruling by the Federal Court in that case, the Company announced in its filings made with the SEC that Larry Hsu had resigned his position as President and CEO.

If, as an Impax shareholder, you wish to participate in a possible lawsuit concerning these time sensitive matters, you are encouraged to swiftly contact us at the contact information below. We particularly encourage long-time stockholders, former employees and any other persons having knowledge about the Company to confidentially contact us. The initial attorney consultation is free of charge and any future legal expenses would be advanced by our firm. All information shall be treated as attorney client privileged and confidential. Although the outcome of litigation is never assured, as a current Impax shareholder, you may be eligible for some form of financial recovery.

The Law Offices of Nicholas Koluncich III, LLC6501 Americas Parkway NEOne Park Square – Suite 820Albuquerque, NM 87110(505) 881-2228FAX (505) 881-4288 nkoluncich@newmexicoclassactions.com

The Law Offices of Nicholas Koluncich III, LLC has been representing individual and institutional investors for over a decade, serving as counsel in numerous securities and derivative litigations in U.S. Federal and state courts.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs